Subtype
Breast Carcinoma by Gene Expression Profile
CI-CAN-00004666Explore in graph →
537 active trials6 approved drugs101 evidence items
- NCIt
- C53553
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004666Explore in graph →
Clinical trials
1,299 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (217)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03671044 | A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients | recruiting | Phase 3 | 657 | Jina Pharmaceuticals Inc.INDUSTRY | 2 | Mar 21, 2025 | clinicaltrials |
| NCT04802876 | Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors(ACROPOLI) | active not recruiting | Phase 2 | 184 | SOLTI Breast Cancer Research GroupOTHER | 1 |
| Mar 21, 2025 |
| clinicaltrials |
| NCT05485766 | Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer | recruiting | Phase 2 | 23 | Okayama UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy(CIRCADIAN) | recruiting | Phase 1 / Phase 2 | 20 | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.OTHER_GOV | 1 | Mar 19, 2025 | clinicaltrials |
| NCT04510129 | A Multicenter Cancer Biospecimen Collection Study | recruiting | — | 1,650 | Cofactor Genomics, Inc.INDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05918133 | A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | active not recruiting | Phase 1 / Phase 2 | 42 | Biotheus Inc.INDUSTRY | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06868758 | Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer | active not recruiting | — | 50 | Chongqing General HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles | not yet recruiting | Phase 4 | 208 | The First Hospital of Jilin UniversityOTHER | 0 | Mar 10, 2025 | clinicaltrials |
| NCT05918328 | Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC | recruiting | Phase 2 | 610 | Henan Cancer HospitalOTHER_GOV | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06851299 | The Clinical Study of the Efficacy and Safety of Trop2-ADC Monotherapy or Combination Immunotherapy Strategy in the Treatment of Advanced Triple-negative Breast Cancer. | recruiting | Phase 2 | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04807192 | CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 40 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05020860 | Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer(RESPONSE) | recruiting | Phase 2 | 185 | Baylor Breast Care CenterOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06849492 | HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer(SHIFT-001) | not yet recruiting | Phase 2 | 120 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06832904 | Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) | recruiting | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT05821686 | Efficacy of Interleukin-2 in Triple Negative Breast Cancer | not yet recruiting | Phase 1 / Phase 2 | 10 | Nova Scotia Health AuthorityOTHER | 0 | Feb 12, 2025 | clinicaltrials |
| NCT06821490 | Validation of TAD in HER-2 with More Than 2 Lymph Nodes(DAD-HER2) | enrolling by invitation | — | 21 | Fundación para la Investigación del Hospital Clínico de ValenciaOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06786026 | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT06805084 | Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas(H/ACA-ER) | active not recruiting | — | 80 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05388149 | Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06795503 | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients | not yet recruiting | Phase 3 | 1,462 | Fudan UniversityOTHER | 0 | Jan 28, 2025 | clinicaltrials |
| NCT06793332 | BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC(BALISTA) | recruiting | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05475678 | Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | recruiting | Phase 2 | 369 | Zhenzhen LiuOTHER_GOV | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03881605 | MRI Screening Versus SYMptom-directed Surveillance for Brain Metastases Among Patients with Triple Negative or HER2+ MBC(SYMPToM) | active not recruiting | N/A | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06782698 | Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients(HoPEx-Breast) | active not recruiting | N/A | 50 | Centro Hospitalar Universitário de Santo AntónioOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06492005 | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 160 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06754059 | Pyrotinib Combined With Trastuzumab for Maintenance Therapy After First-line TH (P) Therapy for HER2+ABC | recruiting | — | 60 | zhangjieOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06746870 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | not yet recruiting | Phase 2 | 148 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 0 | Dec 24, 2024 | clinicaltrials |
| NCT03875573 | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:(Neo-CheckRay) | active not recruiting | Phase 2 | 147 | Jules Bordet InstituteOTHER | 2 | Dec 20, 2024 | clinicaltrials |
| NCT03616886 | Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC(SYNERGY) | active not recruiting | Phase 1 / Phase 2 | 129 | Jules Bordet InstituteOTHER | 2 | Dec 19, 2024 | clinicaltrials |
| NCT06276868 | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | recruiting | Phase 2 | 71 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06636981 | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT06731153 | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | not yet recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06718335 | Pyrotinib in HER2-positive Early Breast Cancer | not yet recruiting | N/A | 156 | Nie JianyunOTHER | 0 | Dec 11, 2024 | clinicaltrials |
| NCT06722599 | Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients(LRNacHER2) | recruiting | — | 171 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06722612 | Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer(TaxCbHER2) | recruiting | — | 2,916 | Shu WangOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06724263 | A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors | not yet recruiting | Phase 2 | 120 | Tasly Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Dec 9, 2024 | clinicaltrials |
| NCT06711055 | Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer(TaxHER) | recruiting | — | 285 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06711068 | Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy(TaxDHER2) | recruiting | — | 8,077 | Shu WangOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06700369 | De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients(NacHER2) | recruiting | — | 519 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06700382 | Different Methods of Capecitabine in Patients With Non-PCR After Neoadjuvant Therapy for TNBC(NeoTNBCX) | recruiting | — | 1,166 | Shu WangOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06692725 | De-escalation of Neoadjuvant Chemotherapy Regimens With Immunotherapy Among TNBC(NacTNBC) | recruiting | — | 380 | Peking University People's HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693024 | Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer(NeraHER2) | recruiting | — | 2,806 | Shu WangOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06693037 | Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy(nonPHER) | recruiting | — | 2,092 | Shu WangOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT05358639 | Combination of Olaparib and Navitoclax in Women with HGSC and TNBC | active not recruiting | Phase 1 | 36 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06532812 | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer(BAH249) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | recruiting | Phase 3 | 310 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT05426486 | A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | active not recruiting | Phase 2 / Phase 3 | 136 | Caigang LiuOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT05403554 | A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers | recruiting | Phase 1 | 70 | Light Chain Bioscience - Novimmune SAINDUSTRY | 2 | Oct 29, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Mar 21, 2025source: clinicaltrials